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Abstract
With declining transmission of malaria in several regions of the world and renewed interest in the elimination of malaria, strategies for
malaria control using antimalarial drugs are being revisited. Drug-based strategies to reduce transmission of malaria need to target the
asymptomatic carriers of infection. Drugs that are effective against gametocytes are few in number, but it may be possible to reduce
gametocyte production by killing the asexual stages, for which more drugs are available. Drugs for use in large-scale programmes must
be safe and tolerable. Strategies include improving access to treatment for malaria with an efﬁcacious drug, intermittent-treatment pro-
grammes, and mass drug administration, with and without screening for malaria. Recent proposals have targeted high-risk groups for
interventions. None of the strategies has been rigorously tested with appropriate control groups for comparison. Because of the lack of
ﬁeld evidence, modelling has been used. Models have shown, ﬁrst, that for long-lasting effects, drug administration programmes should
be linked with vector control, and second, that if elimination is the aim, programmes are likely to be more successful when applied to
smaller populations of a few thousand or less. In order to sustain the gains following the scaling up of vector control and use of arte-
misinin combination therapies (ACTs), strategies that use antimalarials effectively need to be devised and evidence generated for the
most cost-efﬁcient way forward.
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In recent years, a declining trend for malaria transmission
has been observed in sub-Saharan Africa and worldwide
[1–3]. In some part, this decline in reported malaria is attrib-
utable to improved diagnostic testing by the use of parasito-
logical conﬁrmation of a case and a willingness to improve
burden estimates by better deﬁning the populations at risk.
It has been noted that the start of the decline occurred in
some areas before the widespread use of vector control
methods and the advent of artemisinin combination therapy
(ACT) [4]. Scaling up of the use of long-lasting insecticide-
treated bed-nets, indoor residual spraying and ACTs has
probably accelerated this downward trend [5,6]. Important
factors in the reduced transmission seen in many parts of
the world have yet to be identiﬁed, but are likely to be asso-
ciated with improved economic status. Many countries are
currently aiming to eliminate malaria by using a variety of
combinations of interventions. This article reviews the role
of antimalarial treatment of clinical cases, intermittent pre-
ventive treatment (IPT) and schemes of mass drug adminis-
tration (MDA) in malaria elimination.
Asymptomatic Carriage
The paradigm shift that needs to take place when consider-
ation is being given to moving from malaria control to elimi-
nation is in understanding that malaria in endemic areas is an
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asymptomatic infection among semi-immune populations.
The classic symptoms of clinical malaria occur in those with-
out substantial immunity. It is the semi-immune population,
who carry asymptomatic infection, that are responsible for
onward transmission, as they are more likely to remain
untreated and carry parasites for a longer period. Therefore,
in order to reduce malaria transmission, the asymptomatic
parasite pool (the biomass of parasites carried by the popula-
tion) needs to be targeted. Fig. 1 shows the age-speciﬁc inci-
dence of clinical cases and the age-speciﬁc prevalence of
asymptomatic carriage of malaria predicted by a model [7] in
a high-transmission setting (entomological inoculation rate of
85 infectious bites per person-year). It shows that the bur-
den of clinical disease is in the youngest age groups, whereas
the burden of infection is in the older age groups. Gameto-
cytes are the infective stage transmitted to mosquitoes and,
in the case of Plasmodium falciparum, appear in peripheral
blood about 2 weeks after asexual parasites are ﬁrst
detected. Current understanding of gametocyte biology sug-
gests that gametocyte production is dependent on asexual
parasite biomass [8]. In two malaria species, Plasmodium vivax
and Plasmodium ovale, the addition of a dormant liver stage
of the parasite introduces a further challenge for malaria
elimination.
Antimalarial Drug Delivery Strategies
Drug delivery methods that target the asymptomatic pool
are currently not well developed. This is partly because the
asymptomatic pool is not well deﬁned. In areas of moderate
and high endemicity in sub-Saharan Africa, the at-risk groups
for clinical malaria are well deﬁned and targeted. In these
areas, malaria control and drug delivery are mainly focused
on children under the age of 5 years and pregnant women,
as these groups suffer the brunt of disease. However, these
groups do not represent the major population groups har-
bouring the asymptomatic parasite pool. Below, we discuss
strategies that might target the asymptomatic parasite pool.
The widespread use of an efﬁcacious antimalarial for the
treatment of malaria cases alone may have an effect on
malaria transmission. Mboera and Magesa [9] showed trends
of falling sporozoite rates in a highly endemic area in Tanza-
nia when ﬁrst chloroquine and then sulphadoxine–pyrimeth-
amine were introduced, followed by rising sporozoite rates
when resistance to the drugs developed. This phenomenon
has also been reported in areas where ACTs have been
introduced, although no rigorous investigation of the associa-
tion between efﬁcacious drugs and a reduction in transmis-
sion has taken place [5,10–12].
In the setting of massive overdiagnosis and overtreatment
of malaria, as seen in much of the world because of the use of
poorly sensitive clinical diagnosis and self-treatment, it is plau-
sible that the asymptomatic pool is successfully targeted. We
have theorized that, in the late 1990s, increasing access to
treatment and gross overtreatment led to prophylaxis of a
large proportion of the population at risk of malaria and
resulted in falling transmission across East Africa. This was
accomplished through the introduction of integrated manage-
ment of childhood illness, improved public health education,
and the habit of treating all febrile disease as malaria [4]. How-
ever, current treatment policy does not promote overtreat-
ment with antimalarials, for sound reasons. First, the individual
should be treated for the condition that they have, as there is
an increased risk of mortality in those wrongly diagnosed as
having malaria [13]. Second, owing to the poor sensitivity of
clinical diagnosis and the resulting high numbers of false posi-
tives, it is not cost-effective to treat with expensive ACTs
[14]. Third, health statistics generated from clinical diagnosis
mislead control programmes with regard to the true burden
of disease and the appropriate target of control measures.
Many alternative drug delivery strategies have been sug-
gested by different sources. A list of strategies and their deﬁ-
nitions is shown in Table 1, although this is not exhaustive.
A selection of these strategies is outlined here to highlight
the key issues. IPT consists of a full treatment dose of anti-
malarial being given to an asymptomatic individual, regardless
of infection status, at an opportunistic time such as during a
vaccination visit in the case of infants (IPTi), at the time of
regular antenatal appointments in the case of pregnant
women, and at calendar time-points in the case of children
(IPTc). The majority of IPTc studies have been carried out in
children <5 years of age. Only in the highest-transmission
settings will this include the majority of asymptomatic carri-
ers. However, if the age range is increased to include those
10 years of age or even older, it is conceivable that the



















































FIG. 1. Incidence of clinical disease and prevalence of infection by
age in a population from a high endemic setting, entomological inoc-
ulation rate = 85 (estimated using a model [7]).
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increasing the age for IPT makes this similar to MDA. The
aim of MDA when it is used for elimination attempts is
to clear parasites from the population for longer than the
lifespan of a mosquito by including all of the population in a
series of drug rounds.
Two studies of MDA have reported success in combina-
tion with vector control [15,16]. The ﬁrst, by Kaneko et al.
[15], used MDA on an island of fewer than 800 people and
reported elimination of malaria. In the second study, of 17
villages in Cambodia, MDA given once, or in some cases
repeated at day 42, to the entire population successfully
reduced the parasite prevalence from 52.3% to 2.6% after
3 years [16]. As there were no control groups with which
to assess temporal changes in transmission in these studies,
no ﬁrm conclusions on the added beneﬁt of MDA to vector
control can be made, except that substantial decreases in
transmission appear to be possible with this combination.
The emergence and spread of drug resistance is a feared
consequence of MDA. This is more likely when indirect
MDA methods are used, e.g. when antimalarials are added to
salt at low concentrations. This has led to parasites being
exposed to subtherapeutic concentrations of drug and the
selection of drug-resistant parasites [17]. MDA applied
directly with therapeutic concentrations of antimalarials has
not been directly linked to the emergence of antimalarial
resistance, but it is likely to signiﬁcantly increase selection
pressure on the parasite population [17]. Widespread use of
antimalarials such as sulphadoxine–pyrimethamine in routine
clinical practice appears to select resistant parasites [18].
One way to reduce the chance of selecting drug-resistant
parasites is to use combination treatment [19]. The combina-
tion treatment should include a long-acting antimalarial to
provide a period of prophylaxis [20], in order to reduce
transmission and to protect the short-acting partner drug.
Side effects and adverse events are unwanted at an indi-
vidual level, and may affect the acceptability and thus reduce
the effectiveness of MDA. In the Cambodian trial [16], low
doses of primaquine were used in combination with dihyd-
roartemisinin–piperaquine, and no adverse reactions were
reported. Side effects in pregnancy, especially in the ﬁrst tri-
mester, when there is high risk of embryotoxicity, are a con-
cern in MDA programmes. An MDA intervention in Gambia
that investigated this association showed that, among women
who received MDA (artemisinin–sulphadoxine–pyrimeth-
amine), there was no increase in abnormalities in their
infants [21]. Testing for pregnancy should be offered to
women if their pregnancy status is in doubt, especially in the
ﬁrst trimester.
The logistics of carrying out an MDA programme are
complex, especially in large countries. In particular, if there
are large migrant or non-compliant communities, MDA can
fail because of re-introduction of parasites or untreated foci
remaining within the MDA area. Community involvement is
essential for successful MDA interventions, as high coverage
with drugs is needed over a period of several weeks. In
Aneityum and Cambodia, the study teams achieved high
compliance rates by working with the communities [16,22].
To be more effective, in addition to the required high cover-
age, MDA needs to be given within a short time and during
the low-transmission season, when numbers of parasites are
lowest. In order to obtain the maximum effect, it is probably
necessary to incorporate vector control measures such as
long-lasting insecticide-treated bed-nets and indoor residual
spraying before implementing MDA [8]. Repeated rounds of
MDA are likely to be necessary to achieve parasite clearance
from the population and elimination of parasites from people
who experience recrudescent infection following treatment.
In Cambodia, villages that received two rounds of MDA had
better parasite clearance than those that received one round
[16], and in Aneityum, successful eradication was achieved
only after seven rounds of MDA with multiple drugs over
9 weeks [22]. Thus, logistically, MDA is an intensive ordeal.
In order to reduce unnecessary risks, mass screening and
treatment (MSAT) has been proposed. This adds a layer of
TABLE 1. Acronyms and deﬁnitions of strategies for mass drug administration
Acronym Name Deﬁnition
MDA Mass drug administration Simultaneous drug administration, without testing, to the total population of an
island, country, region or district
TMDA Targeted mass drug administration Drug administration to all people living within a small high-risk area, without testing,
such as the population surrounding a case
MSAT or MBS Mass screening and treatment or mass blood survey Screening of all persons irrespective of symptoms and treatment of positives only
FSAT Focal screening and treatment As MSAT, but in a localized area such as a household, neighbourhood, or village
MFT Mass fever treatment Treatment of all people with fever, irrespective of diagnosis
ACD or MSFAT Active case detection or mass screening of fever and treatment Screening of all people with fever and treatment of positives
IPT Intermittent preventive treatment Giving a full treatment dose of an antimalarial to an asymptomatic individual,
regardless of infection status, at an opportunistic time
IPTi Intermittent preventive treatment of malaria in infants IPT of infants (under the age of 1 year) at times of vaccination
IPTp Intermittent preventive treatment of malaria in pregnancy IPT of pregnant women at times of antenatal visits
IPTc or SPC Intermittent preventive treatment of malaria in children or
seasonal prophylaxis in children
IPT of children at deﬁned time periods during the malaria season in seasonal
transmission sites. Usually applies to children under the age of 5 years
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complexity to a programme by requiring that people be
screened with a test for malaria and that only those who are
positive receive treatment. This method relies on a sensitive
diagnostic method, so that as many infected individuals as
possible are detected. Unlike in MDA, prophylaxis is not
given to those who are at risk but not infected or to those
who are infected but carrying parasites at a density below
the level of detection. Currently available screening methods
for use in the ﬁeld are microscopy and rapid diagnostic tests.
Field-based methods for highly sensitive molecular tests are
under development.
With better understanding of the micro-heterogeneity of
malaria and the asymptomatic pool, more targeted
approaches for drug delivery may become feasible. It is
becoming clear that, even in areas of moderate transmission,
malaria is a focal disease [23,24]. It also appears that there is
overdispersion of malaria, a small proportion of the popula-
tion being responsible for most of the transmission [25].
Thus, if these foci, or hot spots, where the high-transmission
populations live, can be identiﬁed and treated, there may be
a major impact on transmission, with reduced exposure to
antimalarial drugs and improved quality and coverage of
malaria control. Both screening and treatment and MDA are
being investigated as tools for targeting foci, namely focal
screening and treatment and targeted MDA.
Drug Options for Malaria Elimination
In this section, we discuss the drugs that are available for
MDA, both for the entire population and for high-risk
groups, such as IPTi and IPTc. Any drug used for MDA must
be extremely safe, acceptable, and efﬁcacious. Safety is a
major concern—a rare adverse event can lead to a signiﬁ-
cant number of cases when a drug is administered to a large
population. In addition, only a small proportion of the popu-
lation carrying parasites or who are at risk of infection
would receive the beneﬁts of treatment at the individual
level, whereas a large proportion of the population, who are
at low or no risk of malaria, would need to receive treat-
ment in order for the beneﬁts to be achieved at the popula-
tion level. Drugs need to be well tolerated by and acceptable
to communities in order to achieve high levels of coverage.
The drug must be efﬁcacious. According to the malaria eradi-
cation research agenda, the target drug proﬁle for MDA
should be as follows: a single dose, effective in eliminating
asexual and sexual parasites in the blood stage, active against
dormant liver stages in the case of P. vivax, and long-acting in
order to prevent new infection [26]. We are some way from
achieving this ideal.
Drugs that reduce gametocyte production or survival are
key to reducing transmission. The 8-aminoquinolines primaqu-
ine and the closely related tafenoquine (under development)
are the only two drugs that are effective against mature ga-
metocytes. Primaquine, when given as a single dose between
30 mg base and 45 mg base, has good efﬁcacy in reducing
P. falciparum gametocyte density to levels below the level of
detection by microscopy [27]. Primaquine also has an effect
against hypnozoites, the dormant liver stage of P. vivax and
P. ovale. However, courses need to be given for between 7
and 14 days to achieve this radical cure. The 8-aminoquino-
lines have not been widely adopted in malaria treatment,
because of the adverse effect of haemolysis in individuals car-
rying the inherited red blood cell enzyme defect glucose-6-
phosphate dehydrogenase deﬁciency. This condition is highly
prevalent in communities that are at risk for malaria. Thus,
primaquine use is generally conﬁned to countries where
the risk/beneﬁt ratio is lowest, i.e. countries that are in
pre-elimination and elimination mode, where the frequency
of treatment is low. A recent review shows that several
commonly used antimalarials—sulphadoxine–pyrimethamine,
amodiaquine, and chloroquine—have some effect on imma-
ture P. falciparum gametocytes where resistance is limited,
but that the artemesinin component in ACTs improves
gametocidal activity by at least 50% [8]. Gametocytes of
other Plasmodium species are metabolically active and are
thus generally sensitive to drugs used to treat asexual
infection [8].
There are several drugs available to treat asexual infec-
tion. Targeting the asymptomatic asexual infections would
reduce gametocyte production and also reduce the number
of early infections that become symptomatic. IPTi and IPTc
in settings of moderate and high endemicity reduce the num-
ber of clinical episodes of malaria [28], primarily through
prophylaxis [29,30]. This means that long-acting, safe, well-
tolerated and efﬁcacious drugs are needed to achieve the
maximum beneﬁt of IPT. Drugs that ﬁt this description are
few in number. Long-acting drugs to which there is little
reported resistance are piperaquine and meﬂoquine, whereas
chloroquine, sulphadoxine–pyrimethamine and amodiaquine
are limited geographically by increasing drug resistance. The
drug combination used in Aneityum Island, Vanuatu in the
1980s [15] was chloroquine, sulphadoxine–pyrimethamine,
and primaquine. However, the use of chloroquine is now
seriously limited, because of the spread of drug resistance
genes in most regions of the world. Artemisinin–sulphadox-
ine–pyrimethamine was investigated in Gambia as a tool for
transmission blocking in 2000, but failed to show a lasting
effect as compared with the control villages [17]. More
recently, artemisinin–sulphadoxine–pyrimethamine showed
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good efﬁcacy in reducing gametocyte carriage in children in
Tanzania, with a higher dose of artemisinin, but the addition
of primaquine was associated with a high risk of haemolysis
[31]. The Cambodian study of MDA, which had no control
villages and applied concurrent vector control, appeared to
show effectiveness at reducing parasitaemia to low levels in
17 villages by the usie of dihydroartemsinin–piperaquine–
primaquine, with no major side effects over 3 years [16].
The effects of dihydroartemsinin–piperaquine and artemeter–
lumefantrine on gametocytes were compared in Kenya, and
showed no difference at day 28 post-treatment [32]. There
was no untreated control group in this study. Trials of IPTi
and IPTc showed that meﬂoquine [33], artemisinin–sulpha-
doxine–pyrimethamine [34], artemisinin–amodiaquine [34],
sulphadoxine–pyrimethamine–amodiaquine [35,36] and dihyd-
roartemsinin–piperaquine [37–39] were efﬁcacious in pre-
venting cases of malaria, but no trial assessed their effect on
gametocytes or transmission. Thus, currently, the best drug
combinations for an elimination programme are likely to be
multiple-day regimens with an artemisinin to kill immature
gametocytes and asexual parasites, a long-acting antimalarial
to kill asexual parasites and offer blood-stage prophylaxis,
and primaquine to kill mature parasites. In Cambodia, where
delayed clearance of parasites with artemesinin has been
noted, atovaquone–proguanil is used for treatment. The use
of atovaquone–proguanil in MDA for transmission reduction
may be evaluated in this area.
Modelling Interventions
Owing to the lack of comprehensive evidence on drug deliv-
ery strategies, modelling the effect of drug-based interven-
tions may help to guide programmes. Models have focused on
P. falciparum. Gametocytaemia and infectiousness of indi-
viduals after different types of treatment, such as artemisinin–
sulphadoxine–pyrimethamine with and without primaquine
[31], have been measured in the ﬁeld, and these results can
be used as model inputs [40]. However, there is still a need
for detailed long-term follow-up of treated individuals to
provide an accurate measurement of their infectiousness to
mosquitoes over time. Models conﬁrm that high coverage
with effective case management has the potential to reduce
transmission, as measured by both the prevalence and inci-
dence of infection [41,42]. In areas of lower transmission,
these effects could be large, approaching those of insecti-
cide-treated nets [40]. However, where transmission levels
are high, effective case management has a proportionately
much smaller effect, owing to both a high rate of asymptomatic
infection, and saturation of the infection in the population.
Nonetheless, good case management is predicted to have a
large indirect impact on total disease burden, particularly
that of severe disease. The role of effective case manage-
ment in limiting malaria epidemics has also been shown to
be important [43].
Models have explored the impact of the widespread use
of the gametocytocidal drugs artemisinin (as part of combina-
tion therapy) and primaquine for case management [40,44].
ACTs are predicted to have a substantially larger impact on
community-wide transmission than previous ﬁrst-line treat-
ments, such as chloroquine and sulphadoxine–pyrimethamine
[40]. This effect is expected to be seen mainly in areas of
low-to-moderate transmission; in areas of high transmission,
a long-acting drug providing prophylaxis could reduce trans-
mission more than a short-acting ACT. In a modelling case
study, the use of ACT was able to explain the observed
reduction in transmission following the widespread introduc-
tion of artesunate–meﬂoquine on the Thai–Myanmar border
[44]. The additional impact of adding primaquine to treat-
ment regimens has been estimated [44,45], and the impact is
likely to be maximized if primaquine can be given about a
week after the initial symptoms, to coincide with the appear-
ance of mature gametocytes [44].
Modelling of MDA includes both MDA and MSAT inter-
ventions [7,45–47]. The predictions of all models agree
with each other and with trial results, showing that mass
treatment interventions used alone only temporarily reduce
transmission unless they are repeated. This is because the
vectors are still in place, and, remaining or imported para-
sites are therefore able to re-invade the population when
blood drug levels decline. For this reason, the beneﬁt of a
one-off round of mass treatment in a high-transmission set-
ting is likely to be negligible. However, the impact may last
for a reasonably long time in areas of lower transmission
where the rate of spread is slow; potentially 2 years or
more if the slide prevalence is £5% [45]. Seasonal dynamics
can be exploited to maximize the effects of mass treatment
by treating in the dry season [45,46,48]. Repeated mass
treatment, when combined with vector control, can dra-
matically reduce transmission, at least temporarily, and
there is a chance of achieving elimination if sufﬁcient cover-
age and a sufﬁcient number of rounds are implemented.
This probability of elimination can be examined with sto-
chastic models [7,45,46]. These results are highly sensitive
to population size: the probabilities of elimination being
achieved through mass treatment are much lower in large
populations that have overlapping mosquito populations.
For example, ﬁve fortnightly rounds of MDA with 80% cov-
erage were estimated to have >30% probability of eliminat-
ing malaria in a population of 1000 with a baseline slide
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prevalence of <8%, whereas the same intervention in a
population of 10 000 had a close to zero probability of
achieving elimination [45]. A model accurately reproduced
the elimination of malaria in a small population on Aneit-
yum, Vanuatu [49].
IPTi, although effective in reducing the clinical burden, is
unlikely to reduce population-wide transmission, as such a
small proportion of the population is treated. However,
IPTc, which reaches a larger proportion of the infectious res-
ervoir, could have a larger impact [50], particularly as the
reservoir can be concentrated in older children.
Conclusion
Strategies involving the use of drugs in elimination appear
likely to be adopted in the near future where countries have
successfully scaled up vector control. However, few strate-
gies have been tested against transmission endpoints and
with appropriate control groups. Logistically and ethically, it
is likely that any large-scale treatment of asymptomatic infec-
tions will be targeted to areas of high risk or will include an
element of testing before treatment to reduce the risks asso-
ciated with MDA, such as side effects and resistance. As
interest is renewed in the use of MDA, evidence of past and
ongoing mass treatment strategies is being collated by the
Cochrane Collaboration and others. Endemic countries are
looking for guidance on this issue, and researchers need sup-
port in order to test strategies, such as MSAT, targeted
MDA, or MDA in combination with IPTc, with careful selec-
tion of appropriate control groups. These studies should be
carried out in different settings, including both P. falciparum
and P. vivax, and on different continents.
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